Global and China Generic Drug

Generic Drug Comprehensive Study by Type (Pure (Non-branded) Generics , Branded Generics , Super Generics), Application (Cardiovascular & Hypertension, Dermatology, Diabetes, Rheumatology, Oncology, Gastrointestinal, Others), Distribution Channel (Online, Offline), End User (Hospital, Clinic, Other) Players and Region - Global Market Outlook to 2030

Generic Drug Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Generic Drug
Generic drugs can enable huge cost-savings as they create competition, driving down prices. In WHO prequalification and in drug regulation, the efficacy of generics is demonstrated by bioequivalence studies. The use of generic drugs significantly decreases the cost of medicines to both patients and governments. Generic drugs are those produced without a license from the innovator company when the patent or other market exclusivity rights have expired on the innovator drug. The increasing chronical disease has protected the growth of the generic drug market in the forecast period.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR5.7%


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.The Players having a strong hold in the market are AbbVie, Gilead Sciences, GlaxoSmithKline, and Amgen. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Generic Drug market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AbbVie (United States), Gilead Sciences (United States), GlaxoSmithKline (GSK) (United Kingdom), Amgen (United States), AstraZeneca (United Kingdom), Bristol-Myers Squibb (United States), Eli Lilly (United States), Novo Nordisk (Denmark), Teva Pharmaceutical Industries Ltd (Israel)  and Bayer (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Novartis AG (Switzerland), Lupin (India), Par Pharmaceutical (United States) and Sun Pharmaceutical Industries Limited (India).

Segmentation Overview
AMA Research has segmented the market of Global Generic Drug market by Type (Pure (Non-branded) Generics , Branded Generics  and Super Generics), Application (Cardiovascular & Hypertension, Dermatology, Diabetes, Rheumatology, Oncology, Gastrointestinal and Others) and Region.



On the basis of geography, the market of Generic Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the Generic Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the Generic Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Expenditure towards the Health Care and Increasing Number of Customer from Online Drug Retailer

Market Growth Drivers:
Growing Old Age Population and Increasing Health Consciousness across the World, Rising Chronic Diseases is Fueling the Market and Government Laws towards the Sale of Drugs without Prescriptions

Challenges:
Growing Competition and Consolidation of Retail Pharmacy Chains

Restraints:
Stringent Government Regulations

Opportunities:
Growing Demand from Emerging Economics such as China, India, Brazil, Philippines, among Others and Government Initiative to Promote Retail Drug in Developing Countries

Market Leaders and their expansionary development strategies

In January 2023, Hikma and Boehringer Ingelheim formed a strategic partnership in the MENA region. This partnership focuses on co-promotion, distribution, and potential co-development of select branded and generic products in the Middle East and North Africa.


Key Target Audience
Retail Drug Companies, Research and Development (R&D) Companies, Research Organization, Federal Agencies, Potential Technology Investors, Regulatory & Government Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Pure (Non-branded) Generics 
  • Branded Generics 
  • Super Generics
By Application
  • Cardiovascular & Hypertension
  • Dermatology
  • Diabetes
  • Rheumatology
  • Oncology
  • Gastrointestinal
  • Others
By Distribution Channel
  • Online
  • Offline

By End User
  • Hospital
  • Clinic
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Old Age Population and Increasing Health Consciousness across the World
      • 3.2.2. Rising Chronic Diseases is Fueling the Market
      • 3.2.3. Government Laws towards the Sale of Drugs without Prescriptions
    • 3.3. Market Challenges
      • 3.3.1. Growing Competition and Consolidation of Retail Pharmacy Chains
    • 3.4. Market Trends
      • 3.4.1. Growing Expenditure towards the Health Care
      • 3.4.2. Increasing Number of Customer from Online Drug Retailer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Generic Drug, by Type, Application, Distribution Channel, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Generic Drug (Value)
      • 5.2.1. Global Generic Drug by: Type (Value)
        • 5.2.1.1. Pure (Non-branded) Generics 
        • 5.2.1.2. Branded Generics 
        • 5.2.1.3. Super Generics
      • 5.2.2. Global Generic Drug by: Application (Value)
        • 5.2.2.1. Cardiovascular & Hypertension
        • 5.2.2.2. Dermatology
        • 5.2.2.3. Diabetes
        • 5.2.2.4. Rheumatology
        • 5.2.2.5. Oncology
        • 5.2.2.6. Gastrointestinal
        • 5.2.2.7. Others
      • 5.2.3. Global Generic Drug by: Distribution Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
      • 5.2.4. Global Generic Drug by: End User (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Clinic
        • 5.2.4.3. Other
      • 5.2.5. Global Generic Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Generic Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Gilead Sciences (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline (GSK) (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amgen (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol-Myers Squibb (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novo Nordisk (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceutical Industries Ltd (Israel) 
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bayer (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Generic Drug Sale, by Type, Application, Distribution Channel, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Generic Drug (Value)
      • 7.2.1. Global Generic Drug by: Type (Value)
        • 7.2.1.1. Pure (Non-branded) Generics 
        • 7.2.1.2. Branded Generics 
        • 7.2.1.3. Super Generics
      • 7.2.2. Global Generic Drug by: Application (Value)
        • 7.2.2.1. Cardiovascular & Hypertension
        • 7.2.2.2. Dermatology
        • 7.2.2.3. Diabetes
        • 7.2.2.4. Rheumatology
        • 7.2.2.5. Oncology
        • 7.2.2.6. Gastrointestinal
        • 7.2.2.7. Others
      • 7.2.3. Global Generic Drug by: Distribution Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
      • 7.2.4. Global Generic Drug by: End User (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Clinic
        • 7.2.4.3. Other
      • 7.2.5. Global Generic Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Generic Drug: by Type(USD Million)
  • Table 2. Generic Drug Pure (Non-branded) Generics  , by Region USD Million (2018-2023)
  • Table 3. Generic Drug Branded Generics  , by Region USD Million (2018-2023)
  • Table 4. Generic Drug Super Generics , by Region USD Million (2018-2023)
  • Table 5. Generic Drug: by Application(USD Million)
  • Table 6. Generic Drug Cardiovascular & Hypertension , by Region USD Million (2018-2023)
  • Table 7. Generic Drug Dermatology , by Region USD Million (2018-2023)
  • Table 8. Generic Drug Diabetes , by Region USD Million (2018-2023)
  • Table 9. Generic Drug Rheumatology , by Region USD Million (2018-2023)
  • Table 10. Generic Drug Oncology , by Region USD Million (2018-2023)
  • Table 11. Generic Drug Gastrointestinal , by Region USD Million (2018-2023)
  • Table 12. Generic Drug Others , by Region USD Million (2018-2023)
  • Table 13. Generic Drug: by Distribution Channel(USD Million)
  • Table 14. Generic Drug Online , by Region USD Million (2018-2023)
  • Table 15. Generic Drug Offline , by Region USD Million (2018-2023)
  • Table 16. Generic Drug: by End User(USD Million)
  • Table 17. Generic Drug Hospital , by Region USD Million (2018-2023)
  • Table 18. Generic Drug Clinic , by Region USD Million (2018-2023)
  • Table 19. Generic Drug Other , by Region USD Million (2018-2023)
  • Table 20. South America Generic Drug, by Country USD Million (2018-2023)
  • Table 21. South America Generic Drug, by Type USD Million (2018-2023)
  • Table 22. South America Generic Drug, by Application USD Million (2018-2023)
  • Table 23. South America Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 24. South America Generic Drug, by End User USD Million (2018-2023)
  • Table 25. Brazil Generic Drug, by Type USD Million (2018-2023)
  • Table 26. Brazil Generic Drug, by Application USD Million (2018-2023)
  • Table 27. Brazil Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 28. Brazil Generic Drug, by End User USD Million (2018-2023)
  • Table 29. Argentina Generic Drug, by Type USD Million (2018-2023)
  • Table 30. Argentina Generic Drug, by Application USD Million (2018-2023)
  • Table 31. Argentina Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 32. Argentina Generic Drug, by End User USD Million (2018-2023)
  • Table 33. Rest of South America Generic Drug, by Type USD Million (2018-2023)
  • Table 34. Rest of South America Generic Drug, by Application USD Million (2018-2023)
  • Table 35. Rest of South America Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 36. Rest of South America Generic Drug, by End User USD Million (2018-2023)
  • Table 37. Asia Pacific Generic Drug, by Country USD Million (2018-2023)
  • Table 38. Asia Pacific Generic Drug, by Type USD Million (2018-2023)
  • Table 39. Asia Pacific Generic Drug, by Application USD Million (2018-2023)
  • Table 40. Asia Pacific Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 41. Asia Pacific Generic Drug, by End User USD Million (2018-2023)
  • Table 42. China Generic Drug, by Type USD Million (2018-2023)
  • Table 43. China Generic Drug, by Application USD Million (2018-2023)
  • Table 44. China Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 45. China Generic Drug, by End User USD Million (2018-2023)
  • Table 46. Japan Generic Drug, by Type USD Million (2018-2023)
  • Table 47. Japan Generic Drug, by Application USD Million (2018-2023)
  • Table 48. Japan Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 49. Japan Generic Drug, by End User USD Million (2018-2023)
  • Table 50. India Generic Drug, by Type USD Million (2018-2023)
  • Table 51. India Generic Drug, by Application USD Million (2018-2023)
  • Table 52. India Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 53. India Generic Drug, by End User USD Million (2018-2023)
  • Table 54. South Korea Generic Drug, by Type USD Million (2018-2023)
  • Table 55. South Korea Generic Drug, by Application USD Million (2018-2023)
  • Table 56. South Korea Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 57. South Korea Generic Drug, by End User USD Million (2018-2023)
  • Table 58. Taiwan Generic Drug, by Type USD Million (2018-2023)
  • Table 59. Taiwan Generic Drug, by Application USD Million (2018-2023)
  • Table 60. Taiwan Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 61. Taiwan Generic Drug, by End User USD Million (2018-2023)
  • Table 62. Australia Generic Drug, by Type USD Million (2018-2023)
  • Table 63. Australia Generic Drug, by Application USD Million (2018-2023)
  • Table 64. Australia Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 65. Australia Generic Drug, by End User USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Generic Drug, by Type USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Generic Drug, by Application USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Generic Drug, by End User USD Million (2018-2023)
  • Table 70. Europe Generic Drug, by Country USD Million (2018-2023)
  • Table 71. Europe Generic Drug, by Type USD Million (2018-2023)
  • Table 72. Europe Generic Drug, by Application USD Million (2018-2023)
  • Table 73. Europe Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 74. Europe Generic Drug, by End User USD Million (2018-2023)
  • Table 75. Germany Generic Drug, by Type USD Million (2018-2023)
  • Table 76. Germany Generic Drug, by Application USD Million (2018-2023)
  • Table 77. Germany Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 78. Germany Generic Drug, by End User USD Million (2018-2023)
  • Table 79. France Generic Drug, by Type USD Million (2018-2023)
  • Table 80. France Generic Drug, by Application USD Million (2018-2023)
  • Table 81. France Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 82. France Generic Drug, by End User USD Million (2018-2023)
  • Table 83. Italy Generic Drug, by Type USD Million (2018-2023)
  • Table 84. Italy Generic Drug, by Application USD Million (2018-2023)
  • Table 85. Italy Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 86. Italy Generic Drug, by End User USD Million (2018-2023)
  • Table 87. United Kingdom Generic Drug, by Type USD Million (2018-2023)
  • Table 88. United Kingdom Generic Drug, by Application USD Million (2018-2023)
  • Table 89. United Kingdom Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 90. United Kingdom Generic Drug, by End User USD Million (2018-2023)
  • Table 91. Netherlands Generic Drug, by Type USD Million (2018-2023)
  • Table 92. Netherlands Generic Drug, by Application USD Million (2018-2023)
  • Table 93. Netherlands Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 94. Netherlands Generic Drug, by End User USD Million (2018-2023)
  • Table 95. Rest of Europe Generic Drug, by Type USD Million (2018-2023)
  • Table 96. Rest of Europe Generic Drug, by Application USD Million (2018-2023)
  • Table 97. Rest of Europe Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 98. Rest of Europe Generic Drug, by End User USD Million (2018-2023)
  • Table 99. MEA Generic Drug, by Country USD Million (2018-2023)
  • Table 100. MEA Generic Drug, by Type USD Million (2018-2023)
  • Table 101. MEA Generic Drug, by Application USD Million (2018-2023)
  • Table 102. MEA Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 103. MEA Generic Drug, by End User USD Million (2018-2023)
  • Table 104. Middle East Generic Drug, by Type USD Million (2018-2023)
  • Table 105. Middle East Generic Drug, by Application USD Million (2018-2023)
  • Table 106. Middle East Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 107. Middle East Generic Drug, by End User USD Million (2018-2023)
  • Table 108. Africa Generic Drug, by Type USD Million (2018-2023)
  • Table 109. Africa Generic Drug, by Application USD Million (2018-2023)
  • Table 110. Africa Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 111. Africa Generic Drug, by End User USD Million (2018-2023)
  • Table 112. North America Generic Drug, by Country USD Million (2018-2023)
  • Table 113. North America Generic Drug, by Type USD Million (2018-2023)
  • Table 114. North America Generic Drug, by Application USD Million (2018-2023)
  • Table 115. North America Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 116. North America Generic Drug, by End User USD Million (2018-2023)
  • Table 117. United States Generic Drug, by Type USD Million (2018-2023)
  • Table 118. United States Generic Drug, by Application USD Million (2018-2023)
  • Table 119. United States Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 120. United States Generic Drug, by End User USD Million (2018-2023)
  • Table 121. Canada Generic Drug, by Type USD Million (2018-2023)
  • Table 122. Canada Generic Drug, by Application USD Million (2018-2023)
  • Table 123. Canada Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 124. Canada Generic Drug, by End User USD Million (2018-2023)
  • Table 125. Mexico Generic Drug, by Type USD Million (2018-2023)
  • Table 126. Mexico Generic Drug, by Application USD Million (2018-2023)
  • Table 127. Mexico Generic Drug, by Distribution Channel USD Million (2018-2023)
  • Table 128. Mexico Generic Drug, by End User USD Million (2018-2023)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Generic Drug: by Type(USD Million)
  • Table 140. Generic Drug Pure (Non-branded) Generics  , by Region USD Million (2025-2030)
  • Table 141. Generic Drug Branded Generics  , by Region USD Million (2025-2030)
  • Table 142. Generic Drug Super Generics , by Region USD Million (2025-2030)
  • Table 143. Generic Drug: by Application(USD Million)
  • Table 144. Generic Drug Cardiovascular & Hypertension , by Region USD Million (2025-2030)
  • Table 145. Generic Drug Dermatology , by Region USD Million (2025-2030)
  • Table 146. Generic Drug Diabetes , by Region USD Million (2025-2030)
  • Table 147. Generic Drug Rheumatology , by Region USD Million (2025-2030)
  • Table 148. Generic Drug Oncology , by Region USD Million (2025-2030)
  • Table 149. Generic Drug Gastrointestinal , by Region USD Million (2025-2030)
  • Table 150. Generic Drug Others , by Region USD Million (2025-2030)
  • Table 151. Generic Drug: by Distribution Channel(USD Million)
  • Table 152. Generic Drug Online , by Region USD Million (2025-2030)
  • Table 153. Generic Drug Offline , by Region USD Million (2025-2030)
  • Table 154. Generic Drug: by End User(USD Million)
  • Table 155. Generic Drug Hospital , by Region USD Million (2025-2030)
  • Table 156. Generic Drug Clinic , by Region USD Million (2025-2030)
  • Table 157. Generic Drug Other , by Region USD Million (2025-2030)
  • Table 158. South America Generic Drug, by Country USD Million (2025-2030)
  • Table 159. South America Generic Drug, by Type USD Million (2025-2030)
  • Table 160. South America Generic Drug, by Application USD Million (2025-2030)
  • Table 161. South America Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 162. South America Generic Drug, by End User USD Million (2025-2030)
  • Table 163. Brazil Generic Drug, by Type USD Million (2025-2030)
  • Table 164. Brazil Generic Drug, by Application USD Million (2025-2030)
  • Table 165. Brazil Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 166. Brazil Generic Drug, by End User USD Million (2025-2030)
  • Table 167. Argentina Generic Drug, by Type USD Million (2025-2030)
  • Table 168. Argentina Generic Drug, by Application USD Million (2025-2030)
  • Table 169. Argentina Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 170. Argentina Generic Drug, by End User USD Million (2025-2030)
  • Table 171. Rest of South America Generic Drug, by Type USD Million (2025-2030)
  • Table 172. Rest of South America Generic Drug, by Application USD Million (2025-2030)
  • Table 173. Rest of South America Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 174. Rest of South America Generic Drug, by End User USD Million (2025-2030)
  • Table 175. Asia Pacific Generic Drug, by Country USD Million (2025-2030)
  • Table 176. Asia Pacific Generic Drug, by Type USD Million (2025-2030)
  • Table 177. Asia Pacific Generic Drug, by Application USD Million (2025-2030)
  • Table 178. Asia Pacific Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 179. Asia Pacific Generic Drug, by End User USD Million (2025-2030)
  • Table 180. China Generic Drug, by Type USD Million (2025-2030)
  • Table 181. China Generic Drug, by Application USD Million (2025-2030)
  • Table 182. China Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 183. China Generic Drug, by End User USD Million (2025-2030)
  • Table 184. Japan Generic Drug, by Type USD Million (2025-2030)
  • Table 185. Japan Generic Drug, by Application USD Million (2025-2030)
  • Table 186. Japan Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 187. Japan Generic Drug, by End User USD Million (2025-2030)
  • Table 188. India Generic Drug, by Type USD Million (2025-2030)
  • Table 189. India Generic Drug, by Application USD Million (2025-2030)
  • Table 190. India Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 191. India Generic Drug, by End User USD Million (2025-2030)
  • Table 192. South Korea Generic Drug, by Type USD Million (2025-2030)
  • Table 193. South Korea Generic Drug, by Application USD Million (2025-2030)
  • Table 194. South Korea Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 195. South Korea Generic Drug, by End User USD Million (2025-2030)
  • Table 196. Taiwan Generic Drug, by Type USD Million (2025-2030)
  • Table 197. Taiwan Generic Drug, by Application USD Million (2025-2030)
  • Table 198. Taiwan Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 199. Taiwan Generic Drug, by End User USD Million (2025-2030)
  • Table 200. Australia Generic Drug, by Type USD Million (2025-2030)
  • Table 201. Australia Generic Drug, by Application USD Million (2025-2030)
  • Table 202. Australia Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 203. Australia Generic Drug, by End User USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Generic Drug, by Type USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Generic Drug, by Application USD Million (2025-2030)
  • Table 206. Rest of Asia-Pacific Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 207. Rest of Asia-Pacific Generic Drug, by End User USD Million (2025-2030)
  • Table 208. Europe Generic Drug, by Country USD Million (2025-2030)
  • Table 209. Europe Generic Drug, by Type USD Million (2025-2030)
  • Table 210. Europe Generic Drug, by Application USD Million (2025-2030)
  • Table 211. Europe Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 212. Europe Generic Drug, by End User USD Million (2025-2030)
  • Table 213. Germany Generic Drug, by Type USD Million (2025-2030)
  • Table 214. Germany Generic Drug, by Application USD Million (2025-2030)
  • Table 215. Germany Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 216. Germany Generic Drug, by End User USD Million (2025-2030)
  • Table 217. France Generic Drug, by Type USD Million (2025-2030)
  • Table 218. France Generic Drug, by Application USD Million (2025-2030)
  • Table 219. France Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 220. France Generic Drug, by End User USD Million (2025-2030)
  • Table 221. Italy Generic Drug, by Type USD Million (2025-2030)
  • Table 222. Italy Generic Drug, by Application USD Million (2025-2030)
  • Table 223. Italy Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 224. Italy Generic Drug, by End User USD Million (2025-2030)
  • Table 225. United Kingdom Generic Drug, by Type USD Million (2025-2030)
  • Table 226. United Kingdom Generic Drug, by Application USD Million (2025-2030)
  • Table 227. United Kingdom Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 228. United Kingdom Generic Drug, by End User USD Million (2025-2030)
  • Table 229. Netherlands Generic Drug, by Type USD Million (2025-2030)
  • Table 230. Netherlands Generic Drug, by Application USD Million (2025-2030)
  • Table 231. Netherlands Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 232. Netherlands Generic Drug, by End User USD Million (2025-2030)
  • Table 233. Rest of Europe Generic Drug, by Type USD Million (2025-2030)
  • Table 234. Rest of Europe Generic Drug, by Application USD Million (2025-2030)
  • Table 235. Rest of Europe Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 236. Rest of Europe Generic Drug, by End User USD Million (2025-2030)
  • Table 237. MEA Generic Drug, by Country USD Million (2025-2030)
  • Table 238. MEA Generic Drug, by Type USD Million (2025-2030)
  • Table 239. MEA Generic Drug, by Application USD Million (2025-2030)
  • Table 240. MEA Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 241. MEA Generic Drug, by End User USD Million (2025-2030)
  • Table 242. Middle East Generic Drug, by Type USD Million (2025-2030)
  • Table 243. Middle East Generic Drug, by Application USD Million (2025-2030)
  • Table 244. Middle East Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 245. Middle East Generic Drug, by End User USD Million (2025-2030)
  • Table 246. Africa Generic Drug, by Type USD Million (2025-2030)
  • Table 247. Africa Generic Drug, by Application USD Million (2025-2030)
  • Table 248. Africa Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 249. Africa Generic Drug, by End User USD Million (2025-2030)
  • Table 250. North America Generic Drug, by Country USD Million (2025-2030)
  • Table 251. North America Generic Drug, by Type USD Million (2025-2030)
  • Table 252. North America Generic Drug, by Application USD Million (2025-2030)
  • Table 253. North America Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 254. North America Generic Drug, by End User USD Million (2025-2030)
  • Table 255. United States Generic Drug, by Type USD Million (2025-2030)
  • Table 256. United States Generic Drug, by Application USD Million (2025-2030)
  • Table 257. United States Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 258. United States Generic Drug, by End User USD Million (2025-2030)
  • Table 259. Canada Generic Drug, by Type USD Million (2025-2030)
  • Table 260. Canada Generic Drug, by Application USD Million (2025-2030)
  • Table 261. Canada Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 262. Canada Generic Drug, by End User USD Million (2025-2030)
  • Table 263. Mexico Generic Drug, by Type USD Million (2025-2030)
  • Table 264. Mexico Generic Drug, by Application USD Million (2025-2030)
  • Table 265. Mexico Generic Drug, by Distribution Channel USD Million (2025-2030)
  • Table 266. Mexico Generic Drug, by End User USD Million (2025-2030)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Generic Drug: by Type USD Million (2018-2023)
  • Figure 5. Global Generic Drug: by Application USD Million (2018-2023)
  • Figure 6. Global Generic Drug: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Generic Drug: by End User USD Million (2018-2023)
  • Figure 8. South America Generic Drug Share (%), by Country
  • Figure 9. Asia Pacific Generic Drug Share (%), by Country
  • Figure 10. Europe Generic Drug Share (%), by Country
  • Figure 11. MEA Generic Drug Share (%), by Country
  • Figure 12. North America Generic Drug Share (%), by Country
  • Figure 13. Global Generic Drug share by Players 2023 (%)
  • Figure 14. Global Generic Drug share by Players (Top 3) 2023(%)
  • Figure 15. Global Generic Drug share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 18. AbbVie (United States) Revenue: by Geography 2023
  • Figure 19. Gilead Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 20. Gilead Sciences (United States) Revenue: by Geography 2023
  • Figure 21. GlaxoSmithKline (GSK) (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. GlaxoSmithKline (GSK) (United Kingdom) Revenue: by Geography 2023
  • Figure 23. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 24. Amgen (United States) Revenue: by Geography 2023
  • Figure 25. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 28. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 29. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 30. Eli Lilly (United States) Revenue: by Geography 2023
  • Figure 31. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 32. Novo Nordisk (Denmark) Revenue: by Geography 2023
  • Figure 33. Teva Pharmaceutical Industries Ltd (Israel)  Revenue, Net Income and Gross profit
  • Figure 34. Teva Pharmaceutical Industries Ltd (Israel)  Revenue: by Geography 2023
  • Figure 35. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Bayer (Germany) Revenue: by Geography 2023
  • Figure 37. Global Generic Drug: by Type USD Million (2025-2030)
  • Figure 38. Global Generic Drug: by Application USD Million (2025-2030)
  • Figure 39. Global Generic Drug: by Distribution Channel USD Million (2025-2030)
  • Figure 40. Global Generic Drug: by End User USD Million (2025-2030)
  • Figure 41. South America Generic Drug Share (%), by Country
  • Figure 42. Asia Pacific Generic Drug Share (%), by Country
  • Figure 43. Europe Generic Drug Share (%), by Country
  • Figure 44. MEA Generic Drug Share (%), by Country
  • Figure 45. North America Generic Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AbbVie (United States)
  • Gilead Sciences (United States)
  • GlaxoSmithKline (GSK) (United Kingdom)
  • Amgen (United States)
  • AstraZeneca (United Kingdom)
  • Bristol-Myers Squibb (United States)
  • Eli Lilly (United States)
  • Novo Nordisk (Denmark)
  • Teva Pharmaceutical Industries Ltd (Israel) 
  • Bayer (Germany)
Additional players considered in the study are as follows:
Novartis AG (Switzerland) , Lupin (India) , Par Pharmaceutical (United States) , Sun Pharmaceutical Industries Limited (India)
Select User Access Type

Key Highlights of Report


Feb 2024 239 Pages 81 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global and China Generic Drug Quantitative research analysis
Global and China Generic Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AbbVie (United States), Gilead Sciences (United States), GlaxoSmithKline (GSK) (United Kingdom), Amgen (United States), AstraZeneca (United Kingdom), Bristol-Myers Squibb (United States), Eli Lilly (United States), Novo Nordisk (Denmark), Teva Pharmaceutical Industries Ltd (Israel)  and Bayer (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Expenditure towards the Health Care " is seen as one of major influencing trends for Generic Drug Market during projected period 2023-2030.
The Generic Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global and China Generic Drug Report?

Have a Query? Click Here

Other Related Reports

Atracurium Comprehensive Study by Type (25mg, 50mg), Application (Hospital, Clinic, ASCs, Others) Players and Region - Global Market Outlook to 2028
$ 3500
Cat Vaccines Comprehensive Study by Type (Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, Recombinant Vaccines), Application (Vete...
$ 3750
Nattokinase Supplement Comprehensive Study by Type (Vegetarian, Contains gelatin), Application (For Cardiovascular Diseases, For Pain), Form (Capsules, Tablets, Liquid, Others), Distribution Channel ...
$ 3450
Herbal Weight Loss Products Comprehensive Study by Type (Tablet, Syrup, Supplements), Application (Fitness Centers, Online Sales, Pharmacies, Hyper Markets), Pills and Supplements (Garnicia Cambogia,...
$ 3450
Botulinum Toxin Comprehensive Study by Type (Botulinum Toxin Type A, Botulinum Toxin Type B, Others), Application (Cosmetic Applications, Therapeutic Applications), End User (Hospitals, Ambulatory Ca...
$ 3500
Bovine-based Collagen for Biomedical Applications Comprehensive Study by Application (Bone Graft Substitutes, Collagen-based Scaffolds, Hemostats, Skin Substitutes, Cartilage Repairs, Others), Major ...
$ 3750